• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Draft Regulation for Drug-Device Combination Product Registration in China

Draft Regulation for Drug-Device Combination Product Registration in China

Friday, 22 January 2021 / Published in Medical Device, NMPA Registration in China

Draft Regulation for Drug-Device Combination Product Registration in China

On January 12, the National Medical Products Administration (NMPA) announced (No.6-2021) the amendment regulation (draft) for the registration of drug-device combination products.

The new draft refines the 2009 version with 8 major changes whilst the definition of drug-device combination products remains unchanged, the purpose of the changes is to clarify the registration requirements and classification method of different drug-device combination products.

The new draft proposed to remove the following clause 6 from the original regulation:

“Applications for combination products, importing to China for the first time, will not be accepted for the following reasons:

–           The market approval of the product has not been obtained from the exporting country

–           The drug contained in the product has not obtained the registration approval from China or the market approval from the country of origin”

The draft also provided the following reasons for removing clause 6:

–           Some of the drugs contained in the combination products may not be regulated in the exporting country hence it could be impossible to obtain the required marketing approval

–           Even if the drug has obtained the marketing approval from the exporting country, the combination product may contain the raw material(s) of the drug with the adoption of a different production process, dosage, intended use etc. from the original drug itself

As a solution, applicants are suggested to refer to the following clause 2 (updated in the new draft) for submitting the appropriate market approval certificate:

–           If the combination product intends to achieve a therapeutic effect on the patient, the applicant shall meet the registration requirements of a medical device in China. Otherwise, if the combination product intends to achieve a drug effect on the patient, the applicant shall meet the registration requirements of a drug product in China.

In addition, the NMPA will implement a new set of technical review guidelines soon for the applicants to follow when registering their products in future.

The NMPA launched a public consultation to solicit comments for the draft. Stay tuned for more updates and let us know if you would like to share your opinions with us before the consultation period ends on January 26, 2021.

By Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: Combination Products, Drug - Medical Device Combination

What you can read next

Health Food Raw Materials and Functions
China medical device clinical evaluation exemption
China medical device clinical evaluation exemption catalogue is open for comments
Drug – Medical Device Combination Products

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.